Browse EX-10 agreements

Execution Version

REGISTRATION RIGHTS AGREEMENT

** **

This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 13, 2026, between Scinai Immunotherapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

This Agreement is made pursuant to the Securities Purchase Agreement, dated as of October 13, 2026, between the Company and the Purchasers named therein (the “Purchase Agreement”).

The Company and each Purchaser hereby agrees as follows:

1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

“Advice” shall have the meaning set forth in Section 6(c).

…

Execution Version

** **

SECURITIES PURCHASE AGREEMENT

** **

This Securities Purchase Agreement (this “Agreement”) is dated as of October 13, 2026, between Scinai Immunotherapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below) and/or Regulation D promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement; and

…

Execution Version

Scinai Immunotherapeutics Ltd.
Jerusalem BioPark, 2nd floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(+972) 8-930-2529

October 13, 2026

To the Holder of Warrants to Purchase Ordinary Shares Represented by American Depositary Shares Issued on April 27, 2026

Re:	Inducement Offer to Exercise Existing Warrants

Dear Holder:

…

EXECUTIVE EMPLOYMENT AGREEMENT

** **

THIS EXECUTIVE EMPLOYMENT AGREEMENT (together with the Schedules hereto, this “Agreement”) is made as of October 9, 2026 (the “Execution Date”).

BETWEEN:

** **

PINEAPPLE FINANCIAL INC., a corporation continued under the Canada Business Corporations Act, whose common shares are listed on the NYSE American LLC (“NYSE American”) under the symbol “PAPL” (the “Company”)

— and —

USMAN MAHER, an individual residing in New York, New York (the “Executive”)

RECITALS

** **

…

FORM OF EMPLOYMENT AGREEMENT

This Employment Agreement (the “Agreement”), dated as of * October 15, 2026* (the “Effective Date”), is entered into by and between Atlas Trinity Tech Limited, a company incorporated in the British Virgin Islands (the “Company” and, together with its subsidiaries, the “ATTT Group”) and Haoyuan Liu (the “Executive”).

WHEREAS, the Company and the Executive wish to enter into an employment agreement whereby the Executive will be employed by the Company in accordance with the terms and conditions stated below;

NOW, THEREFORE, the parties hereby agree as follows:

ARTICLE 1
EMPLOYMENT, DUTIES AND RESPONSIBILITIES

Section 1.01*. Employment. *The Executive shall serve as the Chief Executive Officer of the Company. The Executive hereby accepts such employment and agrees to devote substantially all of the Executive’s time and efforts to promoting the interests of the ATTT Group.

…

** **

Certain exhibits and schedules to this Agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the U.S. Securities and Exchange Commission upon request.

** **

MUTUAL STOCK PURCHASE AND ASSET EXCHANGE AGREEMENT

This Mutual Stock Purchase and Asset Exchange Agreement (this “Agreement”) is entered into as of October 14, 2026 (the “Effective Date”), by and between VIVOS THERAPEUTICS, INC., a Delaware corporation (“Vivos” or the “Purchaser”) and SOD SCIENCES, INC., a Florida corporation (“SOD” or the “Seller” and, together with Vivos, the “Parties”).

RECITALS

A. SOD owns the ReBalU Protocol, the test/treat/retest platform, the pseudohypoxia early-warning test architecture and related patent filings, a marketing agreement with American Health Associates (“AHA”), and a Memorandum of Understanding with Cleveland Clinic Weston.

…

** **

Exhibit 10.2

** **

Execution Version

** **

REGISTRATION RIGHTS AND LOCK-UP AGREEMENT

This Registration Rights and Lock-Up Agreement (this “Agreement”) is made and entered into as of October 14, 2026 and effective as of the Second Effective Time (as defined in the Business Combination Agreement (as defined below)) by and among AtlasClear Holdings, Inc., a Delaware corporation (the “Company”), and the parties listed on the signature page hereto under the heading “Holders” (each, a “Holder” and collectively, together with their respective permitted assigns, the “Holders”). Any capitalized term used but not defined herein will have the meaning ascribed to such term in the Business Combination Agreement.

RECITALS

…

Execution Version

THIS NOTE IS SUBJECT TO CERTAIN TRANSFER AND OTHER RESTRICTIONS SET FORTH HEREIN.

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY COMPARABLE STATE SECURITIES LAW. EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER THIS NOTE NOR ANY PORTION HEREOF MAY BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF UNLESS THE SAME IS REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE AND THE MAKER HAS RECEIVED EVIDENCE OF SUCH EXEMPTION REASONABLY SATISFACTORY TO THE MAKER.

NON-NEGOTIABLE
UNSECURED PROMISSORY NOTE

October 14, 2026 (the “Issue Date”)	$2,500,000

…

Exhibit 10.1 AMENDMENT NO. 4 TO CREDIT AGREEMENT This Amendment NO. 4 TO THE CREDIT AGREEMENT dated as of October 14, 2026 (this “Amendment”), is by and among Conduent Business Services, LLC, a Delaware limited liability company (the “Lead Borrower”), Conduent State & Local Solutions, Inc., a New York corporation (the “CSLS Borrower”), Affiliated Computer Services International B.V., a private limited company (besloten vennootschap met beperkte aansprakelijkheid) organized under the laws of the Netherlands (the “Dutch Borrower”) and, together with the Lead Borrower and the CSLS Borrower, the “Borrowers”), Conduent Incorporated, a New York corporation (“Holdings”), the other Guarantors party hereto, all Non-Extending Revolving Credit Lenders, Lenders comprising Required Lenders and Bank of America, N.A., in its capacities as administrative agent and collateral agent for the Non-Extending Revolving Credit Lenders (in such capacities, the “Administrative Agent”). Capitalized terms used but not defined in this Amendment have the meanings given to such terms in the Amended Credit Agreemen

…

LIMITED WAIVER AGREEMENT

This Limited Waiver Agreement (the “Agreement”), dated as of October 14, 2026, is entered into by and between ECARX Holdings Inc., an exempted company incorporated under the laws of the Cayman Islands with offices located at International House, 1 St. Katharine’s Way, London E1W 1UN, United Kingdom (the “Company”) and the investor identified on the signature pages hereto (the “Investor”). Any term not defined herein shall have the meaning as set forth in the Securities Purchase Agreement (as defined below).

WHEREAS, prior to the date hereof, the Company and the Investor have entered into that certain Securities Purchase Agreement, dated October 30, 2025 (the “Securities Purchase Agreement”), pursuant to which, among other things, the Company (a) issued certain senior convertible notes of the Company to the Investor and (b) agreed to issue to the Investor, in one or more closings, certain additional senior convertible notes of the Company (each, an “Additional Note”, and collectively, the “AdditionalNotes”);

…

** **

**COMPANY SUPPORT AGREEMENT **

This COMPANY SUPPORT AGREEMENT (this “Agreement”), dated as of October [●], 2026, is made by and among Pyrophyte Acquisition Corp. II, a Cayman Islands exempted company limited by shares (“Pyrophyte”), Sakuu Corporation, a Delaware corporation (the “Company”), and the undersigned holder (the “Restricted Company Shareholder”) of shares of the Company’s Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock and Bridge Preferred Stock, in each case, par value $0.0001 per share (“Company Preferred Stock”), and/or shares of the Company’s Common Stock, par value $0.0001 per share (“Company Common Stock”), as applicable (collectively, the “Company Shares”). Pyrophyte, the Company and the Restricted Company Shareholder shall be referred to herein from time to time collectively as the “Parties” and, individually, as a “Party”. Capitalized terms used but not otherwise defined herein, including capitalized terms used in any provisi

…

SPONSOR SUPPORT AGREEMENT

THIS SPONSOR SUPPORT AGREEMENT (this “Agreement”), dated as of October 14, 2026, is entered into by and among Pyrophyte Acquisition Corp. II, a Cayman Islands exempted company (“Pyrophyte”), Pyrophyte Acquisition II LLC, a Delaware limited liability company (the “Sponsor”), and Sakuu Corporation, a Delaware corporation (“Sakuu”).

RECITALS

WHEREAS, as of the date hereof, Sponsor is the record and “beneficial owner” (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange Act”)) of and is entitled to dispose of and vote, in the aggregate, 7,135,721 Pyrophyte Class B Ordinary Shares (the “Owned Shares”; the Owned Shares and any additional Pyrophyte Class A Ordinary Shares (or any securities convertible into or exercisable or exchangeable for Pyrophyte Class A Ordinary Shares) in which Sponsor acquires record or beneficial ownership after the date hereof, including by purchase, as a result of a share dividend, share subdivision, re

…